All Insights
Regulatory GuideGreece

Supplying Generic Medicines to Greece: EOF Framework and Importer Checklist

22 November 2026By Tuli Enterprise Export Team

How Indian generic manufacturers and exporters can supply Greece: EOF routes, documents, labelling and a practical importer checklist.

Understanding the Greek Pharmaceutical Market

Greece is a European Union member state, so its medicine rules follow EU pharmaceutical law. They are enforced nationally by the National Organization for Medicines (EOF, Ethnikos Organismos Farmakon). Generic medicines are widely used in hospitals and community pharmacies, and the market rewards reliable supply and competitive pricing. For Indian manufacturers and exporters, the opportunity is real, but the entry route is different from emerging markets where an importer can register a product directly.

This guide explains how the framework works in practice and what a Greek importer or distributor should have ready before sourcing from India. For other markets, see our country guides.

Who Does What: MAH, Importer and Wholesaler

In Greece, as elsewhere in the EU, a medicine can only be placed on the market if a Marketing Authorisation (MA) exists. The key parties are:

  • Marketing Authorisation Holder (MAH): the legal entity, established in the EU/EEA, responsible for the product, pharmacovigilance and compliance.
  • Manufacturer or importer with a manufacturing/import authorisation: products made outside the EU must be imported by a licensed entity that carries out quality control testing and batch certification by a Qualified Person (QP) in the EU.
  • Licensed wholesale distributor: holds a wholesale distribution authorisation and supplies pharmacies and hospitals.

A distributor cannot simply import an Indian generic with no MA. The product needs an authorisation that covers Greece, and the Indian manufacturing site must be listed in that dossier.

Authorisation Routes for Generics

Depending on the product, an MA may be obtained through one of the following routes. Always confirm current procedures directly with EOF or the relevant EU authority.

  1. National procedure: an application made directly to EOF for a Greek-only authorisation.
  2. Mutual recognition or decentralised procedure: the dossier is assessed by one or more EU member states, and Greece can participate as a concerned state.
  3. Centralised procedure: assessed through the European Medicines Agency and valid across the EU, mainly for certain product categories.
  4. Existing EU authorisation: if a partner already holds an MA for a generic made at an Indian site, supply can be arranged under that authorisation and the relevant variations.

Generics are normally filed with a Common Technical Document (CTD) dossier showing quality, and bioequivalence or other evidence of equivalence to the reference medicine. The route your partner chooses affects the dossier scope and the overall timeline. Because timelines depend on the procedure and regulator workload, no fixed duration should be assumed.

Core Documents Greek Importers Typically Need

A well-prepared supplier should be able to provide the following. Tuli Enterprise supports exporters and buyers with many of these documents through our manufacturing partners.

  • CTD dossier (Modules 1 to 5) in a format suitable for the chosen EU procedure
  • Certificate of Pharmaceutical Product (COPP) issued by the Indian authority
  • Free Sale Certificate
  • Certificate of Analysis (CoA) for each batch
  • Stability data in line with the climatic zone and shelf life claimed
  • Evidence of GMP compliance for the manufacturing site, such as an EU GMP certificate or inspection outcome, as required by the authority
  • Active substance information, including the source and its own compliance documentation
  • Draft Summary of Product Characteristics (SmPC), package leaflet and label text

Our manufacturing partners hold relevant quality certifications, but the buyer and the MAH remain responsible for confirming that site status meets EU requirements for the specific product.

Labelling and Packaging Requirements

Labelling is a frequent cause of delay. For Greece, expect the following:

  • Package leaflet and carton text in Greek, following the EU QRD template structure
  • Product name, strength, pharmaceutical form, batch number and expiry date in the standard format
  • The MA number assigned to the product
  • Braille on the outer carton for the product name, where required
  • Safety features such as a unique identifier and anti-tampering device for prescription medicines, under the EU Falsified Medicines framework

Packaging for Greece may need to be done at an authorised EU site, even if bulk production is in India. Plan this early, since it affects costs and lead time.

Pricing, Reimbursement and Tenders

Medicine prices in Greece are set under national pricing rules, and reimbursement decisions are made separately from marketing authorisation. Hospital demand is typically served through public procurement and tenders. Buyers should check the current pricing and reimbursement rules with the relevant national bodies before committing to volumes, as these can change.

Importer Checklist Before You Place an Order

  1. Confirm the legal route. Identify who is the MAH and whether an MA already covers the product in Greece.
  2. Verify your licences. Make sure your wholesale authorisation, and any import authorisation, are valid and cover the product category.
  3. Check the manufacturing site. The site must appear in the dossier and meet EU GMP expectations.
  4. Request the document pack. Ask for CoA, stability data, COPP and the CTD sections you need.
  5. Agree on packaging and artwork. Settle Greek-language text, serialisation and who handles QP certification.
  6. Define commercial terms. MOQ, batch size, lead time, shelf life at dispatch and payment terms should be written down.
  7. Plan pharmacovigilance. Confirm who handles adverse event reporting and the safety documentation.
  8. Confirm with the regulator. Requirements and forms change, so check with EOF before filing or shipping.

MOQ and Lead Time Expectations

MOQ depends on the product, dosage form and whether you need dedicated packaging. Standard catalogue items from our partners usually carry lower MOQs than products with custom artwork or a new dossier. Lead time is driven by production scheduling, QC release, any EU-site packaging and QP certification. We give a written estimate per product at the quotation stage, rather than a generic promise.

Therapy Areas Often Considered

Greek buyers typically look at anti-infectives, cardiovascular, diabetes, gastrointestinal, pain and respiratory generics. You can browse the range in our product catalogue or by therapy area. If you want a product under your own MA or label, our contract manufacturing service can help you plan formulation, dossier support and packaging with qualified partners.

For more practical guidance, visit our insights library on documentation, registration and sourcing.

Request a Quote for Greece

If you are a Greek importer, distributor or tender buyer looking for Indian generics, send us your product list, strengths, pack sizes and target volumes. Tuli Enterprise, a New Delhi-based merchant exporter and member of PHARMEXCIL and FPME, supplies to over 95 countries. Message us on WhatsApp at wa.me/919654308142, email [email protected], or use our contact form to start a quotation.

Need a supplier for this market?

Tuli Enterprise supplies WHO-GMP certified generics and nutraceuticals worldwide with full registration and export documentation.

Request a Quote